SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

(RTTNews) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment of mitral ...

Wall Street analysts call the CMS TAVR proposal a "clear positive" for the sector, with Edwards Lifesciences, Medtronic, and ...

The FDA has approved Edwards Lifesciences Corp.’s Sapien M3 transcatheter mitral valve replacement system. The U.S. approval, announced last week, comes eight months after the device received CE Mark ...

Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...

Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...

EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced data demonstrating successful patient ...

Medtronic is emerging as the key rival to Edwards Lifesciences for a new type of heart valve Orange County is shaping up to be the stage for a two-horse race for a new type of heart valve. Last month, ...

Federal health officials are asking safety questions about the first artificial heart valve designed to be implanted without major surgery, in advance of a meeting Wednesday to consider broadening its ...

(Reuters) - Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for ...